NEJM and ACC posts report SCOUT-HCM showed mavacamten reduced left ventricular outflow tract obstruction versus placebo in adolescents with obstructive hypertrophic cardiomyopathy, with clinicians noting consistency with adult experience and higher dose needs.
In the phase 3 SCOUT-HCM trial, among adolescents with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor mavacamten led to a significantly greater reduction in left ventricular outflow tract obstruction than placebo.
Mavacamten in adolescents with obstructive HCM. Results from SCOUT-HCM
Overall consistent with what was seen in adults. Requiring higher doses of drug.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare